Recruitment

Recruitment Status
Recruiting
Estimated Enrollment
Same as current

Summary

Conditions
  • Atypical Teratoid/Rhabdoid Tumor
  • Chordoma (Poorly Differentiated or De-differentiated)
  • Epithelioid Sarcoma
  • Malignant Rhabdoid Tumor
  • Other INI1 Negative Malignant Tumors (With PI Approval)
  • Rhabdoid Tumor of the Kidney
Type
Interventional
Phase
Phase 2
Design
Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Younger than 630 years
Gender
Both males and females

Description

This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug or drug combination to learn whether the drug or drug combination works in treating a specific disease. "Investigational" means that the drug combination is being studied. The names ...

This research study is a Phase II clinical trial, which tests the safety and effectiveness of an investigational drug or drug combination to learn whether the drug or drug combination works in treating a specific disease. "Investigational" means that the drug combination is being studied. The names of the study drugs involved in this study are: Nivolumab (OPDIVO) Ipilimumab (YERYOY) This trial is studying whether nivolumab and ipilimumab work to treat INI1-negative cancers. The U.S. Food and Drug Administration (FDA) has not approved combination nivolumab and ipilimumab for the specific diseases in this study but it has been approved for other diseases. Nivolumab and ipilimumab have been tested in children to find out a safe dose of this combination.

Tracking Information

NCT #
NCT04416568
Collaborators
Not Provided
Investigators
Principal Investigator: Suzanne Forrest, MD Dana-Farber Cancer Institute